Abstract:The interaction between programmed cell death ligand 1 (PD-L1), which is expressed on the surface of tumor cells, and programmed cell death 1 (PD-1), which is expressed on T cells, impedes the effective activation of tumor antigen-specific T cells, resulting in the evasion of tumor cells from immune-mediated killing. Blocking the PD-1/PD-L1 signaling pathway has been shown to be effective in preventing tumor immune evasion. PD-1/PD-L1 blocking antibodies have garnered significant attention in recent years within the field of tumor treatments, given the aforementioned mechanism. Furthermore, clinical research has substantiated the efficacy and safety of this immunotherapy across various tumors, offering renewed optimism for patients. However, challenges persist in anti-PD-1/PD-L1 therapies, marked by limited indications and the emergence of drug resistance. Consequently, identifying additional regulatory pathways and molecules associated with PD-1/PD-L1 and implementing judicious combined treatments are imperative for addressing the intricacies of tumor immune mechanisms. This review briefly outlines the structure of the PD-1/PD-L1 molecule, emphasizing the posttranslational modification regulatory mechanisms and related targets. Additionally, a comprehensive overview on the clinical research landscape concerning PD-1/PD-L1 post-translational modifications combined with PD-1/PD-L1 blocking antibodies to enhance outcomes for a broader spectrum of patients is presented based on foundational research.

Recent Findings in the Posttranslational Modifications of PD-L1

The Regulation of N6‐methyladenosine Modification in PD‐L1‐induced Anti‐tumor Immunity

[Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy]

The Nuclear Transportation of PD-L1 and the Function in Tumor Immunity and Progression

Anti-Tumor Potential of Post-Translational Modifications of PD-1

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy

Post-translational Modification of PD-1: Potential Pathways for Cancer Immunotherapy

PD-1 regulation in immune homeostasis and immunotherapy

Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics

Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeutics

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

Regulation of PD-L1 expression in the tumor microenvironment

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Emerging Role of Ubiquitination/deubiquitination Modification of PD-1/PD-L1 in Cancer Immunotherapy

New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer